Specialty Chemicals company Tatva Chintan Pharma Chem announced Q1FY27 results Consolidated Financial Highlights: Revenue from operations for Q1FY27 stood at Rs 1,670.55 million, representing a YoY increase of 42.95% from Rs 1,168.64 million in Q1FY26 and a QoQ growth of 24.53% from Rs 1,341.44 million in Q4FY26. Total income reached Rs 1,698.35 million in Q1FY27 compared to Rs 1,180.19 million in Q1FY26, registering a YoY growth of 43.91%. Profit before exceptional items and tax for Q1FY27 was Rs 224.29 million, an increase of 146.45% from Rs 91.01 million in Q1FY26 and up 35.22% from Rs 165.87 million in Q4FY26. Net profit for the period (PAT) was reported at Rs 159.81 million in Q1FY27, showing a YoY growth of 140.28% compared to Rs 66.51 million in Q1FY26 and a QoQ increase of 54.84% from Rs 103.21 million in Q4FY26. Basic Earnings Per Share (EPS) for Q1FY27 stood at Rs 6.83, compared to Rs 2.84 in Q1FY26 and Rs 4.41 in Q4FY26. Standalone Financial Highlights: Revenue from operations for Q1FY27 was Rs 1,467.02 million, up 34.37% YoY from Rs 1,091.80 million in Q1FY26 and 10.58% QoQ from Rs 1,326.65 million in Q4FY26. Net profit after tax for Q1FY27 stood at Rs 104.46 million, reflecting a YoY growth of 103.51% from Rs 51.33 million in Q1FY26 and a QoQ growth of 15.77% from Rs 90.23 million in Q4FY26. Total income for Q1FY27 was Rs 1,507.35 million, compared to Rs 1,105.49 million in Q1FY26 and Rs 1,322.96 million in Q4FY26. Business Highlights: Capacity Expansion: The Board approved a proposed capacity expansion for various specialty chemicals at a new greenfield unit located at Dahej - III, Gujarat. The project involves the installation of an aggregate reactor capacity of 344 kilolitres (KL) with an estimated investment of Rs 200 Crore. This expansion is expected to be completed within approximately 21 months and will be financed through a combination of internal accruals and debt. Borrowing Limits: The Board approved a proposal to increase the company's borrowing limits from Rs 300 Crore to Rs 1,000 Crore, subject to the approval of members at the ensuing Annual General Meeting. Management Re-appointments: Re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director, and Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors, was approved for a further period of three years from February 1, 2027, to January 31, 2030. Segment Performance: As per Ind AS 108, the company has only one reportable business segment, which is specialty chemicals. Result PDF
Specialty Chemicals company Tatva Chintan Pharma Chem announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, revenue stood at Rs 1,341.44 million, representing a YoY increase of 24.36% from Rs 1,078.64 million in Q4FY25 and a QoQ increase of 2.14% from Rs 1,313.34 million in Q3FY26. Total Income: The total income for Q4FY26 was Rs 1,337.96 million, compared to Rs 1,085.86 million in Q4FY25 (up 23.22% YoY) and Rs 1,330.68 million in Q3FY26 (up 0.55% QoQ). Net Profit: The company reported a net profit of Rs 103.21 million in Q4FY26, marking a significant YoY increase of 902.04% from Rs 10.30 million in Q4FY25, but a QoQ decrease of 31.94% from Rs 151.65 million in Q3FY26. Annual Performance (FY26): Revenue from operations for the full year FY26 was Rs 5,058.58 million, up 32.18% from Rs 3,827.14 million in FY25. Net profit for FY26 increased by 636.11% to Rs 420.54 million from Rs 57.13 million in FY25. Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 stood at Rs 4.41, compared to Rs 0.44 in Q4FY25 and Rs 6.49 in Q3FY26. For the full year FY26, EPS was Rs 17.98. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs 1,326.65 million, up 23.24% YoY from Rs 1,076.48 million in Q4FY25 and down 4.27% QoQ from Rs 1,385.88 million in Q3FY26. Total Income: Total standalone income for Q4FY26 was Rs 1,322.96 million, compared to Rs 1,089.43 million in Q4FY25 and Rs 1,403.22 million in Q3FY26. Net Profit: Standalone net profit for Q4FY26 was Rs 90.23 million, up 724.02% YoY from Rs 10.95 million in Q4FY25 and down 43.55% QoQ from Rs 159.84 million in Q3FY26. Annual Performance (FY26): Standalone revenue from operations for the full year FY26 reached Rs 4,962.96 million, an increase of 35.45% from Rs 3,664.15 million in FY25. Net profit for FY26 stood at Rs 390.82 million, a massive increase compared to Rs 3.27 million in FY25. Business Highlights: Segment Performance: The company operates in only one reportable business segment, which is Specialty Chemicals. Dividend: The Board of Directors recommended a final dividend of Rs 2/- (20%) per equity share of face value Rs 10/- each for the financial year 2025-26, subject to shareholder approval. Auditor Appointments: The Board approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor of the company for the financial year 2026-27. Subsidiaries: The consolidated financial results include the results of two subsidiaries: Tatva Chintan USA Inc. and Tatva Chintan Europe B.V. Result PDF
Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Tatva Chintan Pharma Chem announced Q3FY26 results Revenue: Rs 1,313.34 crore against Rs 858.96 crore during Q3FY25. PBT: Rs 176.58 crore against Rs -2.35 crore during Q3FY25. PAT: Rs 151.65 crore against Rs 1.38 crore during Q3FY25. EPS: Rs 6.49 for Q3FY26. Result PDF